Skip to main content
OpenTrials
Completed

NCT Number: NCT02162875

Schistosoma Mansoni in Mwanza Region, Tanzania

The objective of this study is to determine the strategy for mass drug administration (MDA) which provides the greatest reductions in prevalence and intensity of Schistosoma mansoni in school-aged children after 4 years of intervention.

Completed

Looking for future studies?

Notify Me

Key information

Age range

7 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

National Institute for Mediacal Research

Mwanza, Kagera, Tanzania

About this study

Intestinal schistosomiasis is caused by the blood-dwelling flatworm Schistosoma mansoni. Despite the increasing focus on the use of praziquantel against schistosomiasis infections for the last three decades many areas in Sub-Saharan Africa still have high prevalences and intensities of schistosomiasis especially among school-age children. This is true for the area of Mwanza Region of Tanzania adjacent to Lake Victoria. The study is a six arm study and includes 150 communities (25 in each arm). From each community 100 school children (aged 9-12 years), 100 first year students (aged 7-8 years) and 50 adults (aged 20-55 years) are included, diagnosed and treated with praziquantel using strategies composing of a mixture of community wide treatment (CWT), school-based treatment (SBT) and years without treatment (-T). The 100 school children provided stool specimens on three consecutive days, while the 100 first year students and 50 adults with few exceptions only provided one specimen. The treatment strategies during the 4 years for the different arms are as follows: Arm 1: CWT, CWT, CWT, CWT; Arm 2: CWT, CWT, SBT, SBT; Arm 3: CWT, CWT -T, -T; Arm 4: SBT, SBT, SBT, SBT; Arm 5: SBT, SBT, -T, -T; Arm 6: SBT, -T, SBT, -T.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-All school children and adults who consent to participate can be included

Exclusion criteria

-Those not consenting or with any chronic disease not related to schistosomiasis will be excluded

Treatment and study plan

Praziquantel

Drug

Six different treatment strategies with praziquantel

Other names: no other drugs

Primary outcomes

  1. Effect of Mass drug administration on prevalence and intensity of Schistosoma mansoni among children and adults

    Time frame: May -October 2016 (5 months)

    Prevalence and intensity of Schistosoma mansoni

Secondary outcomes

  1. Mass drug administration coverage

    Time frame: May -October 2016 (5 months)

    Coverage of treatment

Other outcomes

  1. Cost of different treatment arm

    Time frame: May-October 2016 (5 months)

    Cost of different treatment arm

Sponsors and collaborators

Lead sponsor

DBL -Institute for Health Research and Development

Other

Registry information

Official study title

Parasitologic Impact of Different Mass Drug Administration Strategies Against Schistosoma Mansoni in Endemic Areas of Mwanza Region, Tanzania, Where Prevalence is 25% or Above

Acronym: SCORE_PAR

Important dates

Study start
2011
Primary completion
2017
Study completion
2017
First posted
Jun 13, 2014
Registry last updated
Feb 10, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.